PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 2, 20264 citations

Current state of the field and recommendations for middle meningeal artery embolization in chronic subdural hematoma: A Report of the SNIS Standards and Guidelines Committee, Endorsed by ANZSNR and ESMINT.

View Full Paper
JMJustin MascitelliKBKetan R. BulsaraFMFranklin A. Marden

Key Points

  • This work aims to provide recommendations for the use of middle meningeal artery embolization (MMAE) in treating chronic subdural hematoma (cSDH).
  • Conducted a structured literature review on MMAE usage.
  • Graded the strength and quality of evidence based on established criteria.
  • Developed recommendations by consensus from the SNIS Standards and Guidelines Committee.
  • MMAE as adjunctive therapy to surgical drainage recommended to lower recurrence risk (class I, level A).
  • Standalone MMAE in special populations such as high-risk surgical patients is reasonable (class IIa, level B-NR).
  • Assessment for dangerous collaterals is crucial before embolization (class I, level C-EO).

Abstract

BACKGROUND: Middle meningeal artery embolization (MMAE) is increasingly being used for adjunctive and standalone treatment of chronic subdural hematoma (cSDH). The Society of NeuroInterventional Surgery (SNIS) Standards and Guidelines Committee set out to provide up-to-date recommendations on the use of MMAE for the treatment of cSDH. METHODS: A structured literature review was performed pertinent to the use of MMAE. The strength and quality of evidence were graded according to established criteria. Recommendations were developed by consensus of the writing committee with input from the SNIS Standards and Guidelines Committee and the SNIS Board of Directors. RESULTS: Highlighted recommendations are as follows. Recommendation 1: MMAE as an adjunct to surgical drainage is recommended to decrease the risk of recurrence requiring a further intervention and should be balanced against the risk of the procedure (class I, level A). Recommendation 2: standalone MMAE for cSDH in special circumstances/populations such as high-risk surgical patients, those with bleeding diathesis including thrombocytopenia or coagulopathy, or the elderly is reasonable (class IIa, level B-NR). Recommendation 3: practitioners should assess for dangerous collaterals prior to embolization (class I, level C-EO). CONCLUSIONS: The strongest recommendation currently is for MMAE as an adjunct to surgical drainage of cSDH to decrease the risk of recurrence. Ongoing studies will continue to address standalone MMAE, special populations, and technical nuances.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mascitelli et al. (2026) studied this question.

synapsesocial.com/papers/69f5941871405d493affeeabhttps://doi.org/10.1136/jnis-2026-024979
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment: A Guideline From the Society of Vascular and Interventional Neurology Guidelines and Practice Standards Committee2025 · 14 citations
  2. 2Current Status of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: An International Perspective Including Japan2026
  3. 3Middle meningeal artery embolization versus standard of care for chronic subdural hematoma: Meta-analysis of randomized controlled trials2025 · 2 citations
  4. 4Middle meningeal artery embolization in chronic subdural hematoma: a paradigm shift?2026
  5. 5Middle meningeal artery as a pathway to innovative treatments: ARISE III consensus recommendations2026